[go: up one dir, main page]

DE60135983D1 - Verfahren zur reinigung von alphaviralen replikon partikeln - Google Patents

Verfahren zur reinigung von alphaviralen replikon partikeln

Info

Publication number
DE60135983D1
DE60135983D1 DE60135983T DE60135983T DE60135983D1 DE 60135983 D1 DE60135983 D1 DE 60135983D1 DE 60135983 T DE60135983 T DE 60135983T DE 60135983 T DE60135983 T DE 60135983T DE 60135983 D1 DE60135983 D1 DE 60135983D1
Authority
DE
Germany
Prior art keywords
particles
methods
replicant
alphaviral
cleaning
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60135983T
Other languages
English (en)
Inventor
John M Polo
Catherine Greer
Maria Calderon-Cacia
La Vega Daniel Del Jr
Thomas W Dubensky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Application granted granted Critical
Publication of DE60135983D1 publication Critical patent/DE60135983D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Powder Metallurgy (AREA)
  • Disintegrating Or Milling (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
DE60135983T 2000-05-31 2001-05-31 Verfahren zur reinigung von alphaviralen replikon partikeln Expired - Lifetime DE60135983D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20837600P 2000-05-31 2000-05-31
PCT/US2001/018021 WO2001092552A2 (en) 2000-05-31 2001-05-31 Method for the purification of alphavirus replicon particles

Publications (1)

Publication Number Publication Date
DE60135983D1 true DE60135983D1 (de) 2008-11-13

Family

ID=22774372

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60135983T Expired - Lifetime DE60135983D1 (de) 2000-05-31 2001-05-31 Verfahren zur reinigung von alphaviralen replikon partikeln

Country Status (9)

Country Link
US (4) US6767699B2 (de)
EP (1) EP1285080B1 (de)
AT (1) ATE409749T1 (de)
AU (1) AU2001275191A1 (de)
CA (1) CA2410948C (de)
DE (1) DE60135983D1 (de)
DK (1) DK1285080T3 (de)
ES (1) ES2312447T3 (de)
WO (1) WO2001092552A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
EP2332573A1 (de) 2001-05-31 2011-06-15 Novartis Vaccines and Diagnostics, Inc. Chimäre Alphavirus-Replikonpartikel
US7045335B2 (en) * 2001-09-06 2006-05-16 Alphavax, Inc. Alphavirus replicon vector systems
US7195905B2 (en) * 2001-12-10 2007-03-27 Baxter Healthcare S.A. Enveloped virus vaccine and method for production
DK1501921T4 (da) 2002-04-30 2012-10-08 Oncolytics Biotech Inc Forbedrede virusrensningsmetoder
CA2500661A1 (en) 2002-10-01 2004-04-15 Chiron Corporation Anti-cancer and anti-infectious disease compositions and methods for using same
WO2004055167A2 (en) * 2002-12-13 2004-07-01 Alphavax, Inc. Alphavirus particles and methods for preparation
DK1585812T3 (en) * 2002-12-13 2017-04-10 Alphavax Inc MULTI-ANTI-ANTI-ANTI-VIRUS REPLICATE PARTICLES AND PROCEDURES
US7442381B2 (en) * 2003-03-20 2008-10-28 Alphavax, Inc. Alphavirus replicons and helper constructs
PT1651666E (pt) * 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
JP5065024B2 (ja) * 2004-05-18 2012-10-31 アルファバックス，インコーポレイティド Ｔｃ−８３由来アルファウイルスベクター、粒子および方法
WO2006078294A2 (en) 2004-05-21 2006-07-27 Novartis Vaccines And Diagnostics Inc. Alphavirus vectors for respiratory pathogen vaccines
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
EP1736538A1 (de) * 2005-06-21 2006-12-27 Cytos Biotechnology AG Prozess für die preparative Reinigung von Virus-ähnlichen Partikeln (VLPs)
KR100760525B1 (ko) * 2006-04-13 2007-10-04 김재만 병원성 미생물의 무증폭 다중 정량 검출킷트 및 검출방법
WO2008085557A2 (en) 2006-09-12 2008-07-17 Alphavax, Inc. Alphavirus replicon particles encoding il- 12 as immunological adjuvants
EP2061508B1 (de) 2006-09-12 2014-10-15 Alphavax, Inc. An protein-antigene angepasste alphavirus replikons als immunologisches adjuvant
EP2099485B1 (de) * 2006-11-03 2018-03-21 AlphaVax, Inc. Zusammensetzungen aus alphaviren oder alphavirus replikon partikeln und dazugehörende methoden
PL2183368T3 (pl) 2007-06-21 2016-12-30 Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych
ES2525707T3 (es) 2008-12-01 2014-12-29 Alphavax, Inc. Uso de microRNAs para el control de ácidos nucleicos colaboradores de virus
US8425922B2 (en) 2009-01-05 2013-04-23 EpitoGenesis, Inc. Adjuvant compositions and methods of use
US10072307B1 (en) 2009-01-23 2018-09-11 Colorado State University Research Foundation Isolation of viruses using anionic resin beads
US20120128714A1 (en) 2009-04-08 2012-05-24 Wolchok Jedd D Alphavirus Replicon Particles Expressing TRP2
SG186915A1 (en) 2010-07-30 2013-02-28 Emd Millipore Corp Chromatography media and method
WO2012048276A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
WO2012178118A1 (en) 2011-06-24 2012-12-27 Epitogenesis Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
EP3068866B1 (de) 2013-11-16 2018-04-25 Terumo BCT, Inc. Zellenexpansion in einem bioreaktor
EP3122866B1 (de) 2014-03-25 2019-11-20 Terumo BCT, Inc. Passives ersetzen von medien
SG11201700030UA (en) 2014-09-02 2017-02-27 Emd Millipore Corp High surface area fiber media with nano-fibrillated surface features
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
WO2016093926A1 (en) 2014-12-08 2016-06-16 Emd Millipore Corporation Mixed bed ion exchange adsorber
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
ES2941967T3 (es) 2015-12-23 2023-05-29 Valneva Austria Gmbh Vacuna contra el virus del Zika
EP3464565A4 (de) 2016-05-25 2020-01-01 Terumo BCT, Inc. Zellexpansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
WO2018184028A2 (en) 2017-03-31 2018-10-04 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
CA3073234A1 (en) 2017-09-21 2019-03-28 Valneva Se Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3
NL2022538B1 (en) 2019-02-08 2020-08-19 Academisch Ziekenhuis Groningen Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof.
EP4314244A1 (de) 2021-03-23 2024-02-07 Terumo BCT, Inc. Zellerfassung und -erweiterung
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
WO2024149832A1 (en) 2023-01-12 2024-07-18 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE
WO2024163370A1 (en) * 2023-01-30 2024-08-08 Thermo Finnigan Llc Separation of long oligonucleotides

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466788A (en) * 1985-03-07 1995-11-14 Mycogen Plant Science, Inc. Subgenomic promoter
ES8800988A1 (es) 1985-04-05 1987-12-16 Meloy Lab Procedimiento de producir interferona humana.
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
AU7780687A (en) 1986-07-23 1988-02-10 Aphton Corp. Immunogens and improved methods of making immunogens
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5093239A (en) 1988-05-02 1992-03-03 Eastman Kodak Company Reagents for detecting oxidase positive microorganisms
US5614404A (en) 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5026686A (en) 1989-02-01 1991-06-25 Washington University Antiviral peptides
US5185440A (en) 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
EP1001032A3 (de) 1989-08-18 2005-02-23 Chiron Corporation Rekombinante Retroviren um Vektorkonstruktionen an Zielzellen zu liefern
CA2094608A1 (en) 1990-10-22 1992-04-23 John D. Taylor Dna construct for providing rna therapy
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
WO1994017813A1 (en) 1993-02-08 1994-08-18 Paravax, Inc. Defective sindbis virus vectors that express toxoplasma gondii p30 antigens
DE4315109A1 (de) 1993-05-06 1994-11-10 Inst Pflanzengenetik & Kultur Verfahren und Vektorkonstrukt zur Expressionssteigerung von Transgenen
DE69333216T2 (de) 1993-07-06 2004-06-24 Université de Nice-Sophia Antipolis Vektor, enthält ein bei ARN-Polymerase-III transcriptes Virus-Gen
US5837503A (en) 1993-07-07 1998-11-17 Universite De Nice-Sophia-Antipolis Vector containing viral gene transcribed by RNA polymerase III and methods for use
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
ATE215989T1 (de) * 1993-09-15 2002-04-15 Chiron Corp Rekombinanter alphavirus vektor
US5591579A (en) 1993-12-21 1997-01-07 Washington University Indicator cell line for detecting RNA viruses and method therefor
IL112371A0 (en) 1994-01-25 1995-03-30 Res Dev Foundation A novel protein from aedes albopictus cells and methods for its use
US5498537A (en) * 1994-03-09 1996-03-12 Cellco, Inc. Serum-free production of packaged viral vector
US5532154A (en) 1994-03-21 1996-07-02 Research Development Foundation Mutated alpha virus
SE9401091D0 (sv) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
GB9406498D0 (en) 1994-03-31 1994-05-25 Smithkline Beecham Biolog Novel compounds
SE9401709D0 (sv) 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5797870A (en) 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
AU722196B2 (en) * 1995-08-30 2000-07-27 Genzyme Corporation Chromatographic purification of adenovirus and AAV
WO1997016169A1 (en) 1995-11-01 1997-05-09 Chiron Corporation Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space
EP0871747A1 (de) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunstimulierung vermittelt durch genmodifizierte dendritische zellen
AU2051297A (en) 1996-02-15 1997-09-02 Chiron Corporation Gene therapy method using fgf-5
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
WO1997038087A2 (en) 1996-04-05 1997-10-16 Chiron Corporation Alphaviral vector with reduced inhibition of cellular macromolecular synthesis
AU3210997A (en) 1996-05-24 1997-12-09 University Of Maryland At Baltimore Dna vaccines for eliciting a mucosal immune response
US5843712A (en) 1996-06-06 1998-12-01 The Trustees Of Columbia University In The City Of New York Sindbis virus expression system for recombinant antibody production
US6489167B1 (en) 1996-09-25 2002-12-03 The Government Of The United States As Represented By The Secretary Of The Department Of Human Services Retroviral packaging cassettes amplified in the cytoplasm by autocatalytic Togavirus vectors
EP0932693A1 (de) 1996-10-10 1999-08-04 Henrik Garoff Alphavirus-retrovirus vektoren
WO1998026084A1 (en) 1996-12-09 1998-06-18 Wolfgang Andreas Renner Expression of active interferon beta 1 using recombinant rna replicons
US6261823B1 (en) * 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6261570B1 (en) 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
AU8847798A (en) 1997-08-15 1999-03-08 Inex Pharmaceuticals Corporation Semliki forest virus vectors for gene transfer into non-endothelial cardiovascular cells
US6060308A (en) 1997-09-04 2000-05-09 Connaught Laboratories Limited RNA respiratory syncytial virus vaccines
ES2245042T3 (es) 1997-09-24 2005-12-16 The Regents Of The University Of California Vectores de lentivirus de no primates y sistemas de empaquetamiento.
US6475780B1 (en) 1997-11-14 2002-11-05 Aventis Pasteur Limited Alphavirus vectors for paramyxovirus vaccines
DE69835369T2 (de) 1997-11-14 2007-08-23 Sanofi Pasteur Ltd., Toronto Alphavirus-vektoren
AU1710699A (en) 1997-12-18 1999-07-05 G.D. Searle & Co. Venezuelan equine encephalitis virus vectors expressing tumor-associated antigens to induce cancer immunity

Also Published As

Publication number Publication date
WO2001092552A3 (en) 2002-05-23
US20120231526A1 (en) 2012-09-13
US6767699B2 (en) 2004-07-27
CA2410948A1 (en) 2001-12-06
US20050112752A1 (en) 2005-05-26
US20100055128A1 (en) 2010-03-04
DK1285080T3 (da) 2008-12-01
AU2001275191A1 (en) 2001-12-11
US20020015945A1 (en) 2002-02-07
ATE409749T1 (de) 2008-10-15
CA2410948C (en) 2012-07-17
ES2312447T3 (es) 2009-03-01
WO2001092552A2 (en) 2001-12-06
EP1285080A2 (de) 2003-02-26
EP1285080B1 (de) 2008-10-01

Similar Documents

Publication Publication Date Title
DE60135983D1 (de) Verfahren zur reinigung von alphaviralen replikon partikeln
DE602005012382D1 (de) Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren
DK1651666T3 (da) Alfavirus-baserede cytomegalovirusvacciner
DE60129695D1 (de) Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
PH12019502003A1 (en) Cyclic sulfamide compounds and methods of using same
ATE465266T1 (de) Zusammensetzungen und verfahren zur verpackung von alpavirus-vektoren
PH12020500222A1 (en) Nucleic acid molecules and uses thereof
MX2019000252A (es) Administracion viral oncolitica pseudotipada de polipeptidos terapeuticos.
WO2005035556A3 (en) Sars-coronavirus virus-like particles and methods of use
MXPA03000626A (es) Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c.
IL144371A0 (en) Her-2/neu fusion proteins
MX2024001134A (es) Meganucleasas manipuladas especificamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b.
EA202190907A1 (ru) Репликоны на основе альфавируса для введения биотерапевтических средств
ATE384785T1 (de) Herstellung von viren, virusisolaten, und impfstoffen
TW200635596A (en) Pyridazinone compounds
IN2015DN02546A (de)
WO2010047830A3 (en) Agents for hcv treatment
SA521422495B1 (ar) مستضدات البروستاتا المستحدثة واستخداماتها
MX2019015304A (es) Amortiguador de lavado para cromatografia de intercambio cationico.
DK1519944T3 (da) Fremgangsmåder til fremstilling af fibrinogen
RS51402B (en) IMMUNOSTIMULATORY COMBINATIONS FOR PROPHYLAXIS AND TREATMENT OF HEPATITIS C
ATE321853T1 (de) Humanische pellino-polypeptide
WO2003072725A3 (en) Recombinant negative strand virus rna expression systems and vaccines
WO2005011571A3 (en) Hepatitis virus core proteins as vaccine platforms and methods of use thereof
ATE427119T1 (de) Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition